In agreement with this phenomenon, removing iron from tumor cells, both in vitro and in vivo, by the treatment of iron chelators, dietary iron depletion, phlebotomy, and interference with the hepcidin–ferroportin axis has shown significant success in cancer therapy [57,58,59]. The gene discussed is SLC40A1; the disease is cancer.